Press releases
- Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
- Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
- Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
- Innate Pharma Announces Its Participation in Upcoming Investor Conferences
- Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
- Outcome of Innate Pharma’s 2024 Annual General Meeting
- Innate Pharma: Clarification Regarding SAR443579 Designation
- Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
- Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
- Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.99 |
---|---|
High | 1.99 |
Low | 1.94 |
Bid | 1.96 |
Offer | 1.99 |
Previous close | 1.98 |
Average volume | 0.00 |
---|---|
Shares outstanding | 80.97m |
Free float | 60.81m |
P/E (TTM) | -- |
Market cap | 159.51m EUR |
EPS (TTM) | -0.0939 EUR |
Data delayed at least 15 minutes, as of Jun 25 2024.
More ▼